Paper42908554PubMed
LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.
Zhao Y and 5 others. Front Oncol, 2026.
Cite this record
ConductScience Library. LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab. Papers, record 42908554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42908554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.
- Journal
- Front Oncol
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-24
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39747344 | Application of the Lasso regularisation technique in mitigating overfitting in air quality prediction models. | Sci Rep | 2025 | https://conductscience.org/library/papers/39747344 | PubMed |
| 2 | 20808728 | Regularization Paths for Generalized Linear Models via Coordinate Descent. | J Stat Softw | 2010 | https://conductscience.org/library/papers/20808728 | PubMed |
| 3 | 30596875 | PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. | Ann Intern Med | 2019 | https://conductscience.org/library/papers/30596875 | PubMed |
| 4 | 25569120 | Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. | BMJ | 2015 | https://conductscience.org/library/papers/25569120 | PubMed |
| 5 | 41060708 | Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis. | Hepatol Res | 2026 | https://conductscience.org/library/papers/41060708 | PubMed |
| 6 | 37843628 | Sequencing Systemic Therapy in Hepatocellular Carcinoma. | Curr Treat Options Oncol | 2023 | https://conductscience.org/library/papers/37843628 | PubMed |
| 7 | 41409240 | Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepatocellular carcinoma. | Front Oncol | 2025 | https://conductscience.org/library/papers/41409240 | PubMed |
| 8 | 20175033 | Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. | Semin Liver Dis | 2010 | https://conductscience.org/library/papers/20175033 | PubMed |
| 9 | 28130846 | AASLD guidelines for the treatment of hepatocellular carcinoma. | Hepatology | 2018 | https://conductscience.org/library/papers/28130846 | PubMed |
| 10 | 34027864 | Cyberknife Radiosurgery in Hepatocellular Carcinoma. | J Coll Physicians Surg Pak | 2021 | https://conductscience.org/library/papers/34027864 | PubMed |
| 11 | 20010215 | Assessing the performance of prediction models: a framework for traditional and novel measures. | Epidemiology | 2010 | https://conductscience.org/library/papers/20010215 | PubMed |
| 12 | 31954495 | Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. | J Hepatol | 2020 | https://conductscience.org/library/papers/31954495 | PubMed |
| 13 | 37047482 | Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047482 | PubMed |
| 14 | 36435358 | Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States. | Clin Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36435358 | PubMed |
| 15 | 35799264 | Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35799264 | PubMed |
| 16 | 39211358 | Regularized regression can improve estimates of multivariate selection in the face of multicollinearity and limited data. | Evol Lett | 2024 | https://conductscience.org/library/papers/39211358 | PubMed |
| 17 | 17099194 | Decision curve analysis: a novel method for evaluating prediction models. | Med Decis Making | 2006 | https://conductscience.org/library/papers/17099194 | PubMed |
| 18 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 19 | 25271081 | Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25271081 | PubMed |
| 20 | 38363984 | Using stepwise regression to address multicollinearity is not appropriate. | Int J Surg | 2024 | https://conductscience.org/library/papers/38363984 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42908554
GET https://conductscience.org/api/papers/v1/42908554/references?page=2